Multicenter study of the safety and effectiveness of intracranial aneurysm treatment with the p64MW-HPC flow modulation device.

Background and Purpose: The new p64 flow diverter with hydrophilic polymer coating (HPC) was designed to reduce thrombogenicity. To date, it is unclear how antithrombogenic surface modifications affect neoendothelialization and thrombus formation in patients with unruptured intracranial aneurysms. The purpose of this study was to evaluate the safety and effectiveness of the p64MW-HPC in the treatment of unruptured aneurysms of small to giant size and of both the anterior and posterior circulation.
Materials and Methods: Between March 2020 and October 2022 all patients with unruptured intracranial aneurysms treated with the p64MW-HPC were included at five neurovascular centers. Demographic data, aneurysm characteristics, antiplatelet therapy, procedural complications, and clinical and angiographic outcomes were recorded.
Results: A total of 100 patients with 100 unruptured intracranial aneurysms met the inclusion criteria. Eighty-three aneurysms were classified as saccular, 12 aneurysms were fusiform, 4 aneurysms dissecting, and 1 aneurysm was blister-like. Dual antiplatelet therapy with Clopidogrel and Aspirin was given in 68 cases, and with Ticagrelor and Aspirin in 24 cases. Technical issues with deployment were encountered in 14 cases (torsion ( n  = 3), foreshortening ( n  = 8), and incomplete opening ( n  = 3)). Ischemic stroke occurred in a total of seven cases. In one patient a wire perforation and subsequent severe ICH occurred. Complete aneurysm occlusion at angiographic follow-up (mean time = 7 months) was seen in 73% and adequate occlusion in 93%.
Conclusion: This study is the largest multicenter study to date documenting the safety and effectiveness of the new antithrombogenic p64MW-HPC in the treatment of unruptured intracranial aneurysms of the anterior and posterior circulation.
Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DF: Medtronic—Consulting, Proctoring, Cerenovous—Consulting, Microvention—Consulting, Proctoring, Research Support, Penumbra—Research Support, Stryker—Consulting, Research Support, Balt USA—Consulting, Research Support, Siemens—Research Support, MENTICE-Vascular Simulations—Consultant, Neurogami—Stock Holder, Consultant, Marblehead—Consultant, Stock Holder, RAPID.AI—Consultant, RAPID Medical—Consultant, Qapel Medical—Honorarium, Consultant, Arsenal Medical—Consultant, Phenox Medical—Consultant, Scientia Medical—SAB, Consultant, Stock Holder, NVMed—SAB, Stockholder, Perfuze—SAB, Consultant, Vesalio—Consultant. JK: Phenox—Consulting. MH: speaker, consultant, and proctoring honoraria for Microvention, Phenox, Stryker, Cerenovus, Medtronic, Balt.